The 17 advisers fired last month by Robert F. Kennedy Jr. urged alternatives to ACIP be organized to limit further ...

In a memo, CEO Stéphane Bancel said the job cuts are needed to align the struggling vaccine maker’s cost structure with the ...

Despite battling drugs from BridgeBio and Pfizer, Amvuttra beat Wall Street expectations with results CEO Yvonne Greenstreet ...

A potentially billion-dollar acquisition of Gilgamesh Pharmaceuticals suggests big pharma may finally be willing to place ...

Prasad's exit ends a tumultuous tenure during which he led a reworking of agency guidelines on COVID vaccines and his office ...

The White House set a 60-day deadline for drugmakers to agree on “most favored nation” prices for Medicaid as well as for ...

The fast-selling GLP-1 drug matched Lilly's older medicine Trulicity in a closely watched cardiovascular outcomes trial, ...

Frazier was among the most active venture investors in 2024, according to analysts at William Blair, backing 17 private life ...

The vaccine maker’s board intends to recommend a pending offer from investment firms Nordic Capital and Permira, which would ...

The abrupt exit of the former CBER director raises questions about the FDA’s leadership. For now, newly appointed CDER head ...

Wall Street analysts suggested the FDA’s unexpected change in stance might reflect pressure from advocacy groups and a rebuke ...

The company plans to direct resources away from a drug developed by subsidiary Recognify Life Sciences and toward Atai’s ...